Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, ESAs, Antiemetics, Bisphosphonates, Opioids, NSAIDs), By Region (North America, Europe), And Segment Forecasts, 2023

Quick Summary:

In navigating the increasingly complex terrain of the global cancer supportive care drugs market, reliable, updated insights are essential for strategic decision-making. Our comprehensive market research report provides you with an in-depth understanding of shifting trends and predictive forecasts driving a market that is projected to reach significant heights.

The report demystifies key growth and restraining factors, such as the rising global cancer prevalence and the introduction of biosimilars and targeted treatments. It highlights variations in treatment preferences across developed and developing regions, reflecting differences in disposable income levels and reimbursement scenarios. Another pivotal area explored within the report is the impact of patent expiration on blockbuster drugs and the unfolding opportunities this presents around the launch of biosimilars into the market.

Our Cancer Supportive Care Drugs Market report offers unrivaled insights into specific market segments such as G-CSFs and antiemetics. It presents a geographical analysis that predicts market behavior in regions like North America, setting you on the path to informed, strategic planning.

The global cancer supportive care drugs market size is expected to reach USD 12.17 billion by 2030. The market is expected to decline at a CAGR of -1.26% from 2023 to 2030. This decline is due to factors, such as the launch of biosimilar and approval & uptake of targeted treatments for cancer, which have lesser side effects than traditional chemotherapy drugs. The growing cancer prevalence, high adoption & dependency on traditional treatments, such as chemotherapy, in the developing region, and the rising geriatric population are some of the prominent factors that drive the market growth. According to Globocan, the number of new cancer cases is expected to reach 28.4 million within the next two decades, with a rise of 47% from 2020.

In addition, in developing regions, such as Asian and African countries, due to less disposable income levels and lack of proper reimbursement scenarios, chemotherapy is the most widely preferred cancer treatment compared to other costly targeted therapies. However, the growing adoption of targeted therapies and biosimilars in Europe and the U. S. impedes the market growth. The patent expiration of blockbuster drugs, such as Amgen Inc.’s Neupogen and Neulasta and Johnson & Johnson Services, Inc.’s Procrit/Eprex, is another factor that hampers the market growth. Furthermore, the COVID-19 pandemic has had a significant impact on cancer care. There was a substantial decline in hospital visits, cancer screenings, surgeries, and therapy amid the pandemic.

However, the impact of the pandemic has declined and conditions are getting back to normal in many regions from the second quarter of 2021. Key players are addressing the opportunity of drug patient expiration and thus, are launching biosimilars in the market. The launch of biosimilars has supported expanded access to affordable care for cancer patients. For instance, in June 2020, Pfizer Inc. received the U. S. FDA approval for NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta. It reduces the incidence of febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive anticancer medications. In November 2019, Novartis AG received the FDA approval for Ziextenzo, its biosimilar version of pegfilgrastim. The product was commercialized in Europe in 2018.

Cancer Supportive Care Drugs Market Report Highlights

The G-CSFs (Granulocyte-colony Stimulating Factors) segment accounted for the highest share in 2022. It is a primary treatment option for cancer-related neutropenia
The antiemetics segment is expected to show positive growth during the forecast period due to the launch of newer drugs, such as Cinvanti, Sustol, and Varubi
North America and other developed regional markets are expected to decline over the forecast period
The declining sales in developed markets can be attributed to the launch & rapid uptake of multiple biosimilar & restrictions on opioid prescription

This product will be delivered within 1-3 business days.

Chapter 1 Methodology And Scope

1.1 Market Segmentation And Scope
1.1.1 Segment Definitions
1.1.1.1 Therapeutic Class
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations

Chapter 2 Executive Summary

2.1 Market Snapshot
2.2 Therapeutic Class Snapshot
2.3 Competitive Landscape Snapshot

Chapter 3 Cancer Supportive Care Drugs Market Variables, Trends & Scope

3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Industry Value Chain Analysis
3.4 Supply Demand Analysis
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Growing Cancer Prevalence And Increase In Number Of People Receiving Chemotherapy
3.5.1.2 Large Number Of Side Effects Associated With The Cancer Treatment
3.5.2 Market Restraint Analysis
3.5.2.1 Rising Popularity Of Targeted Therapies For The Treatment Of Cancer In Developed Countries
3.5.2.1 Safety Issues Associated With Supportive Care Agents
3.5.3 Industry Opportunity Analysis
3.5.3.1 Development Of Safer Alternatives For Erythropoiesis-Stimulating Agents And Pain Management Products And Launch Of Biosimilars
3.5.4 Industry Challenges
3.5.4.1 Less Developed Cancer Supportive Cancer Market In Low- And Middle-Income Countries (Lmics)
3.6 Cancer Supportive Care Drugs Market Analysis Tools
3.6.1 Industry Analysis - Porter’s
3.6.2 Pestle Analysis

Chapter 4 Cancer Supportive Care Drugs Market - Segment Analysis, By Therapeutic Class, 2018 - 2030 (USD Million)

4.1 Cancer Supportive Care Drugs Market: Therapeutic Class Movement Analysis
4.2 Cancer Supportive Care Drugs Market: Therapeutic Class Estimates And Forecasts, (USD Million)
4.3 G-Csfs(Granulocyte-Colony Stimulating Factors)
4.3.1 G-Csfs (Granulocyte-Colony Stimulating Factors) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.4 Esas (Erythropoiesis Stimulating Agents)
4.4.1 Esas (Erythropoiesis Stimulating Agents) Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.5 Antiemetics
4.5.1 Antiemetics Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.6 Bisphosphonates
4.6.1 Bisphosphonates Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.7 Opioids
4.7.1 Opioids Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.8 Nsaids And Others
4.8.1 Nsaids And Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Cancer Supportive Care Drugs Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)

5.1 Cancer Supportive Care Drugs: Regional Outlook
5.1.1 North America
5.1.1.1 North America Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.1.2 U.S.
5.1.1.2.1 U.S. Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.1.2.2 Key Country Dynamics
5.1.1.2.3 Disease Prevalence
5.1.1.2.4 Regulatory Framework
5.1.1.2.5 Competitive Scenario
5.1.1.3 Canada
5.1.1.3.1 Canada Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.1.3.2 Key Country Dynamics
5.1.1.3.3 Disease Prevalence
5.1.1.3.4 Regulatory Framework
5.1.1.3.5 Competitive Scenario
5.1.2 Europe
5.1.2.1 Europe Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.2 Uk
5.1.2.2.1 Uk Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.2.2 Key Country Dynamics
5.1.2.2.3 Disease Prevalence
5.1.2.2.4 Regulatory Framework
5.1.2.2.5 Competitive Scenario
5.1.2.3 Germany
5.1.2.3.1 Germany Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.3.2 Key Country Dynamics
5.1.2.3.3 Disease Prevalence
5.1.2.3.4 Regulatory Framework
5.1.2.3.5 Competitive Scenario
5.1.2.4 France
5.1.2.4.1 France Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.4.2 Key Country Dynamics
5.1.2.4.3 Disease Prevalence
5.1.2.4.4 Regulatory Framework
5.1.2.4.5 Competitive Scenario
5.1.2.5 Italy
5.1.2.5.1 Italy Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.5.2 Key Country Dynamics
5.1.2.5.3 Disease Prevalence
5.1.2.5.4 Regulatory Framework
5.1.2.5.5 Competitive Scenario
5.1.2.6 Spain
5.1.2.6.1 Spain Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.6.2 Key Country Dynamics
5.1.2.6.3 Disease Prevalence
5.1.2.6.4 Regulatory Framework
5.1.2.6.5 Competitive Scenario
5.1.2.7 Denmark
5.1.2.7.1 Denmark Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.7.2 Key Country Dynamics
5.1.2.7.3 Disease Prevalence
5.1.2.7.4 Regulatory Framework
5.1.2.7.5 Competitive Scenario
5.1.2.8 Sweden
5.1.2.8.1 Sweden Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.8.2 Key Country Dynamics
5.1.2.8.3 Disease Prevalence
5.1.2.8.4 Regulatory Framework
5.1.2.8.5 Competitive Scenario
5.1.2.9 Norway
5.1.2.9.1 Norway Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2.9.2 Key Country Dynamics
5.1.2.9.3 Disease Prevalence
5.1.2.9.4 Regulatory Framework
5.1.2.9.5 Competitive Scenario
5.1.3 Asia Pacific
5.1.3.1 Asia Pacific Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3.2 Japan
5.1.3.2.1 Japan Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3.2.2 Key Country Dynamics
5.1.3.2.3 Disease Prevalence
5.1.3.2.4 Regulatory Framework
5.1.3.2.5 Competitive Scenario
5.1.3.3 China
5.1.3.3.1 China Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3.3.2 Key Country Dynamics
5.1.3.3.3 Disease Prevalence
5.1.3.3.4 Regulatory Framework
5.1.3.3.5 Competitive Scenario
5.1.3.4 India
5.1.3.4.1 India Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3.4.2 Key Country Dynamics
5.1.3.4.3 Disease Prevalence
5.1.3.4.4 Regulatory Framework
5.1.3.4.5 Competitive Scenario
5.1.3.5 South Korea
5.1.3.5.1 South Korea Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3.5.2 Key Country Dynamics
5.1.3.5.3 Disease Prevalence
5.1.3.5.4 Regulatory Framework
5.1.3.5.5 Competitive Scenario
5.1.3.6 Australia
5.1.3.6.1 Australia Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3.6.2 Key Country Dynamics
5.1.3.6.3 Disease Prevalence
5.1.3.6.4 Regulatory Framework
5.1.3.6.5 Competitive Scenario
5.1.3.7 Thailand
5.1.3.7.1 Thailand Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3.7.2 Key Country Dynamics
5.1.3.7.3 Disease Prevalence
5.1.3.7.4 Regulatory Framework
5.1.3.7.5 Competitive Scenario
5.1.4 Latin America
5.1.4.1 Latin America Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.4.2 Brazil
5.1.4.2.1 Brazil Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.4.2.2 Key Country Dynamics
5.1.4.2.3 Disease Prevalence
5.1.4.2.4 Regulatory Framework
5.1.4.2.5 Competitive Scenario
5.1.4.3 Mexico
5.1.4.3.1 Mexico Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.4.3.2 Key Country Dynamics
5.1.4.3.3 Disease Prevalence
5.1.4.3.4 Regulatory Framework
5.1.4.3.5 Competitive Scenario
5.1.4.4 Argentina
5.1.4.4.1 Argentina Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.4.4.2 Key Country Dynamics
5.1.4.4.3 Disease Prevalence
5.1.4.4.4 Regulatory Framework
5.1.4.4.5 Competitive Scenario
5.1.5 MEA
5.1.5.1 MEA Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.5.2 South Africa
5.1.5.2.1 South Africa Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.5.2.2 Key Country Dynamics
5.1.5.2.3 Disease Prevalence
5.1.5.2.4 Regulatory Framework
5.1.5.2.5 Competitive Scenario
5.1.5.3 Saudi Arabia
5.1.5.3.1 Saudi Arabia Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.5.3.2 Key Country Dynamics
5.1.5.3.3 Disease Prevalence
5.1.5.3.4 Regulatory Framework
5.1.5.3.5 Competitive Scenario
5.1.5.4 UAE
5.1.5.4.1 UAE Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.5.4.2 Key Country Dynamics
5.1.5.4.3 Disease Prevalence
5.1.5.4.4 Regulatory Framework
5.1.5.4.5 Competitive Scenario
5.1.5.5 Kuwait
5.1.5.5.1 Kuwait Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.5.5.2 Key Country Dynamics
5.1.5.5.3 Disease Prevalence
5.1.5.5.4 Regulatory Framework
5.1.5.5.5 Competitive Scenario

Chapter 6 Competitive Landscape

6.1 Company Categorization
6.1.1 Strategy Mapping
6.1.2 New Product Launch
6.1.3 Partnerships
6.1.4 Acquisition
6.1.5 Collaboration
6.2 Company Market Share Analysis, 2022
6.3 Company Profiles
6.3.1 Amgen, Inc.
6.3.1.1 Company Overview
6.3.1.2 Financial Performance
6.3.1.3 Product Benchmarking
6.3.1.4 Strategic Initiatives
6.3.2 Merck & Co., Inc.
6.3.2.1 Company Overview
6.3.2.2 Financial Performance
6.3.2.3 Product Benchmarking
6.3.2.4 Strategic Initiatives
6.3.3 Johnson & Johnson Services, Inc.
6.3.3.1 Company Overview
6.3.3.2 Financial Performance
6.3.3.3 Product Benchmarking
6.3.3.4 Strategic Initiatives
6.3.4 Heron Therapeutics, Inc.
6.3.4.1 Company Overview
6.3.4.2 Financial Performance
6.3.4.3 Product Benchmarking
6.3.4.4 Strategic Initiatives
6.3.5 Novartis Ag
6.3.5.1 Company Overview
6.3.5.2 Financial Performance
6.3.5.3 Product Benchmarking
6.3.5.4 Strategic Initiatives
6.3.6 Gsk Plc
6.3.3.1 Company Overview
6.3.3.2 Financial Performance
6.6.3.3 Product Benchmarking
6.6.3.4 Strategic Initiatives
6.3.7 F. Hoffmann-La Roche Ltd.
6.3.7.1 Company Overview
6.3.7.2 Financial Performance
6.3.7.3 Product Benchmarking
6.3.7.4 Strategic Initiatives
6.3.8 Helsinn Healthcare Sa
6.3.8.1 Company Overview
6.3.8.2 Financial Performance
6.3.8.3 Product Benchmarking
6.3.8.4 Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Global Cancer Supportive Care Drugs Market, By Region, 2018 - 2030 (USD Million)
TABLE 5 Global Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 6 North America Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 7 North America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 8 U.S. Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 9 Canada Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 10 Europe Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 11 Europe Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 12 UK Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 13 Germany Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 14 France Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 15 Italy Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 16 Spain Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 17 Denmark Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 18 Sweden Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 19 Norway Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 20 Asia Pacific Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 21 Asia Pacific Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 22 Japan Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 23 China Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 24 India Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 25 South Korea Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 26 Australia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 27 Thailand Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 28 Latin America Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 29 Latin America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 30 Brazil Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 31 Mexico Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 32 Argentina Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 33 MEA Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 34 MEA Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 35 South Africa Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 36 Saudi Arabia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 37 UAE Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 38 Kuwait Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Cancer supportive care drugs market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Commodity Flow Approach
FIG. 10 Market outlook (2022)
FIG. 11 Penetration and growth prospect mapping
FIG. 12 Penetration and growth prospect mapping
FIG. 13 Cancer supportive care drugs market driver impact
FIG. 14 Global population by age group, 2016, 2021, & 2027
FIG. 15 Cancer supportive care drugs market restraint impact
FIG. 16 PESTEL analysis
FIG. 17 Porter’s five forces analysis
FIG. 18 Cancer Supportive Care Drugs therapeutic class outlook: Key takeaways
FIG. 19 Cancer supportive care drugs market: Therapeutic class movement analysis (USD Million)
FIG. 20 G-CSFs (Granulocyte-colony Stimulating Factors), 2018 - 2030 (USD Million)
FIG. 21 ESAs (Erythropoiesis Stimulating Agents) market, 2018 - 2030 (USD Million)
FIG. 22 Antiemetics market, 2018 - 2030 (USD Million)
FIG. 23 Bisphosphonates market, 2018 - 2030 (USD Million)
FIG. 24 Opioids market, 2018 - 2030 (USD Million)
FIG. 25 NSAIDs and others market, 2018 - 2030 (USD Million)
FIG. 26 Regional outlook, 2022 & 2030
FIG. 27 Regional marketplace: Key takeaways
FIG. 28 North America SWOT analysis
FIG. 29 North America Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 30 U.S. key country dynamics
FIG. 31 U.S. Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 32 Canada key country dynamics
FIG. 33 Canada Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 36 Europe SWOT analysis
FIG. 37 Europe Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 38 U.K. key country dynamics
FIG. 39 U.K. Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 40 Germany key country dynamics
FIG. 41 Germany Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 42 Spain key country dynamics
FIG. 43 Spain Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 44 France key country dynamics
FIG. 45 France Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 46 Italy key country dynamics
FIG. 47 Italy Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 48 Denmark key country dynamics
FIG. 49 Denmark Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 50 Sweden key country dynamics
FIG. 51 Sweden Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 52 Norway key country dynamics
FIG. 53 Norway Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 54 Asia Pacific SWOT analysis
FIG. 55 Asia Pacific Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 56 Japan key country dynamics
FIG. 57 Japan Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 58 China key country dynamics
FIG. 59 China Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 60 India key country dynamics
FIG. 61 India Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 62 Australia key country dynamics
FIG. 63 Australia Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 64 South Korea key country dynamics
FIG. 65 South Korea Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 66 Thailand key country dynamics
FIG. 67 Thailand Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 68 Latin America SWOT analysis
FIG. 69 Latin America Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 70 Brazil key country dynamics
FIG. 71 Brazil Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 72 Mexico key country dynamics
FIG. 73 Mexico Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 74 Argentina key country dynamics
FIG. 75 Argentina Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 76 Middle East and Africa SWOT analysis
FIG. 77 MEA Cancer supportive care drugs market, 2018 - 2030 (USD Million).
FIG. 78 South Africa key country dynamics
FIG. 79 South Africa Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 80 Saudi Arabia key country dynamics
FIG. 81 Saudi Arabia Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 82 UAE key country dynamics
FIG. 83 UAE Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 84 Kuwait key country dynamics
FIG. 85 Kuwait Cancer supportive care drugs market, 2018 - 2030 (USD Million)
FIG. 86 Heat map analysis
FIG. 87 Company market position analysis (2022)
FIG. 88 Consumer behavior analysis
FIG. 89 Market differentiators
FIG. 90 Company market position analysis, 2022